Psilocybin-Assisted Therapy for Cancer

(PAT-MIND Trial)

This trial tests psilocybin-assisted therapy for adults with advanced cancer who feel hopeless or distressed about their illness. Researchers aim to determine if this therapy is feasible, safe, and acceptable by testing different doses of psilocybin (a psychedelic compound) combined with either mindfulness-based or standard therapy. Participants will be randomly assigned to one of four groups, each with a different combination of psilocybin dose and therapy. Adults with advanced cancer who feel demoralized or experience existential distress might be suitable candidates for this trial. As a Phase 2 trial, this research focuses on measuring the treatment's effectiveness in an initial, smaller group, offering participants a chance to contribute to potentially groundbreaking therapy.

Studies have shown that psilocybin, a substance found in certain mushrooms, is generally safe when used with psychological support. Research indicates that a 25 mg dose of PEX010 psilocybin is well-tolerated by people with cancer. For example, one study found this dose was safe and helped reduce symptoms in patients with alcohol use disorder. Another study showed it was safe for people experiencing anxiety and depression related to cancer.

Safety data for the 5 mg dose of PEX010 psilocybin is also encouraging. Research suggests that psilocybin therapy is safe when given with support, although most studies focus on higher doses. Ongoing studies aim to confirm safety at different doses, including 5 mg.

Researchers are excited about psilocybin-assisted therapy for cancer patients because it offers a unique approach to managing the psychological distress often associated with cancer. Unlike traditional options such as antidepressants or counseling, psilocybin, the active ingredient in these treatments, works by potentially altering perception and mood through its effects on serotonin receptors in the brain. This can lead to profound changes in mood and outlook, potentially providing relief from anxiety and depression in just one or two sessions. Furthermore, the integration of psilocybin with standard or mindfulness-based psychological support could enhance therapy's effectiveness, offering a holistic approach to improving patients' quality of life.

Research has shown that psilocybin therapy can help reduce anxiety and depression in cancer patients. Studies have found that about half of the participants experience long-term relief from symptoms like depression after just one dose combined with therapy. In this trial, participants will receive either a 25 mg or 5 mg dose of psilocybin combined with therapy. Specifically, the 25 mg dose has been linked to significant decreases in anxiety and depression for cancer patients. Additionally, research suggests that psilocybin-assisted therapy can improve the overall quality of life for those with advanced cancer. The 5 mg dose also shows promise in alleviating cancer-related anxiety and depression. This trial studies both doses to understand their full potential in providing psychological relief for advanced cancer patients.²³⁶⁷⁸